chufangao/CTO huggingface dataset:
Clinical trial NCT03628144: Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
Official title: The Use of Immunonutrition to Reduce Toxicities From Concurrent Chemotherapy and Radiotherapy for Treatment of Unresectable Stage IIIA-B Non-Small Cell Lung Cancer (NSCLC)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funding unavailable
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-31
Primary completion date: 2022-09-30
Completion date: 2023-09-30
Clinical trial NCT04277663: The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
Official title: A Phase 3, Open-label, Multicenter Study, IBI310 in Combination With IBI308 and IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue the study after consultation with investigators
Enrollment: 136.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-04-17
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Plan to share individual participant data: NO
Clinical trial NCT01582776: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma
Official title: A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Sponsor: The Lymphoma Academic Research Organisation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 317.0 (ACTUAL)
Number of arms: 1.0
Start date: 2012-10-03
Primary completion date: 2018-07-11
Completion date: 2022-05-20
Plan to share individual participant data: NO
Clinical trial NCT05956275: USG-Guided Infiltration Popliteal Artery Capsule Knee Block Versus Adductor Canal Block Application as Postoperative Analgesia
Official title: Comparison Between USG-Guided Infiltration Popliteal Artery Capsule Knee Block Versus Adductor Canal Block Application as Postoperative Analgesia in Total Knee Prosthesis Under General Anesthesia: Randomized Clinical Trial
Sponsor: Siirt Training and Research Hospital (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-08
Primary completion date: 2021-10-01
Completion date: 2021-10-02
Plan to share individual participant data: NO
IPD sharing description: This study is a thesis that I did and presented two years ago. The raw data has not been backed up after going through statistical analysis.
Clinical trial NCT04641962: A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy
Official title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess the Efficacy, Safety and Tolerability of ASP0367 in Participants With Primary Mitochondrial Myopathy
Acronym: MOUNTAINSIDE
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to failure to meet the pre-specified criteria for efficacy
Enrollment: 34.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-05-17
Primary completion date: 2024-05-08
Completion date: 2024-05-08
Plan to share individual participant data: NO
IPD sharing description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under Sponsor Specific Details for Astellas.
Clinical trial NCT05588440: A Clinical Study of ONCT-808 in Subjects with Relapsed or Refractory B-Cell Malignancies
Official title: Phase 1/2 Multi-Center Study to Evaluate the Safety and Efficacy of ONCT-808 in Adult Subjects with Relapsed or Refractory Aggressive B-Cell Malignancies
Sponsor: Oncternal Therapeutics, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Based on the available clinical data and capital requirements for continued development, the Company has decided to terminate this study.
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-05-09
Primary completion date: 2024-09-12
Completion date: 2024-09-12
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03425006: Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
Official title: Phase II Study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Administrative reasons
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-18
Primary completion date: 2021-06-17
Completion date: 2021-10-11
Plan to share individual participant data: NO
Clinical trial NCT05475665: Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
Official title: A Randomized, Double-blind, Multicenter, Placebo-control, Parallel Group Phase # Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
Sponsor: Handok Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 157.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-14
Primary completion date: 2023-03-30
Completion date: 2023-06-13
Clinical trial NCT04634344: Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
Official title: A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD2269 in Patients With Metastatic Castration Resistant Prostate Cancer
Sponsor: Dizal Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to reasons of internal business strategy, not related to study or site conduct.
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-12
Primary completion date: 2022-05-05
Completion date: 2022-05-05
Plan to share individual participant data: NO
Clinical trial NCT03282669: TC02 Obese Women Using It Morphine vs PCA IV Hydromorphone for Post-Cesarean Analgesia
Official title: Randomized Controlled Trial Evaluating the Transcutaneous Carbon Dioxide Measurements in Obese Women Using Intrathecal Morphine Versus Patient-Controlled Intravenous Hydromorphone for Post-Cesarean Analgesia
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Change in institutional policy. Change in resources available.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-31
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT03360448: AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure
Official title: Randomized, Phase 3, Placebo-Controlled Double-Blind, Multicenter Trial of a One Time Intracoronary Administration of Ad5.hAC6 Gene Transfer for Patients With Reduced Left Ventricular Heart Failure
Acronym: FLOURISH
Sponsor: Renova Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Clinical development plans and strategy for RT-100 being re-evaluated
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-30
Primary completion date: 2020-06-30
Completion date: 2023-06-30
Plan to share individual participant data: UNDECIDED
IPD sharing description: Blinded study - de-identified participant data to become available after completion of study.
Clinical trial NCT04370548: DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)
Official title: A Phase 3 Multi-Center, Double-Blind, Placebo-Controlled, Randomized Study of DARE-BV1 in the Treatment of Bacterial Vaginosis
Sponsor: Daré Bioscience, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 307.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-16
Primary completion date: 2020-11-30
Completion date: 2020-12-07
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03193814: Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer
Official title: Study Evaluating the Safety and Efficacy of FOLFOX Plus Apatinib or FOLFIRI Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer
Acronym: XHZL
Sponsor: Wuhan Union Hospital, China (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Inadequate patient enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-01
Primary completion date: 2022-12-01
Completion date: 2024-12-01
Clinical trial NCT03102996: Preserve-Transplant Study
Official title: Preservation of Kidney Function in Kidney Transplant Recipients by Alkali Therapy (Preserve-Transplant Study): a Multi-center Randomized Single-blind Placebo- Controlled Trial
Sponsor: University of Zurich (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 240.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-12
Primary completion date: 2021-06-29
Completion date: 2021-07-26
Clinical trial NCT02509039: A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
Official title: A Phase 1, Multi-center, Open-label Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of CC-122 Administered Orally to Adult Japanese Subjects With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Replaced it with another clinical trial.
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-09-02
Primary completion date: 2023-05-09
Completion date: 2023-05-09
Clinical trial NCT03411031: Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
Official title: A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple Myeloma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor no longer providing drug
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-04
Primary completion date: 2021-02-18
Completion date: 2021-11-04
Clinical trial NCT01253070: Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Official title: A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients &gt;/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 54.0 (ACTUAL)
Number of arms: 1.0
Start date: 2011-04-01
Primary completion date: 2014-10-31
Completion date: 2021-04-15
Clinical trial NCT03162562: The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
Official title: Prospective Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Oregovomab and Hiltonol® as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Advanced Epithelial Cancer of Ovarian, Tubal, or Peritoneal Origin
Sponsor: CanariaBio Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor Decision to discontinue long-term follow-up
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-05-30
Primary completion date: 2020-11-05
Completion date: 2020-11-05
Plan to share individual participant data: NO
Clinical trial NCT03733249: Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Official title: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Sponsor: Bellicum Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Enrollment: 187.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-01-31
Primary completion date: 2020-06-30
Completion date: 2023-04-14
Baseline population: HSCT safety population: All enrolled patients who received hematopoietic stem cell transplantation
Clinical trial NCT01509339: Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis
Official title: Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis
Sponsor: Case Western Reserve University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Lab unable to measure vancomycin levels in Sputum
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2012-01-31
Primary completion date: 2021-12-23
Completion date: 2021-12-23
Clinical trial NCT04475549: Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
Official title: A Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Individuals With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
Sponsor: Tisento Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study terminated due to enrollment challenges.
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-13
Primary completion date: 2022-01-23
Completion date: 2022-01-23
Plan to share individual participant data: NO
Clinical trial NCT03661567: Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer
Official title: A Prospective, Randomized, Controlled Phase Ⅱ Study of Preventively Use of Methylprednisolone After Split-course Chemoradiotherapy to Reduce the Risk of Radiation-induced Pulmonary Injury For Bulky Local Advanced None-small Cell Lung Cancer
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: slow enrollment
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-09
Primary completion date: 2021-09-10
Completion date: 2021-09-10
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02633293: An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
Official title: An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Sponsor: United Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Inhaled treprostinil became commercially available in the US following its approval for PH-ILD
Enrollment: 243.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-15
Primary completion date: 2021-08-01
Completion date: 2021-08-01
Baseline population: Safety Population
Clinical trial NCT03300947: Psilocybin for Treatment of Obsessive Compulsive Disorder
Official title: Psilocybin for Treatment of Obsessive Compulsive Disorder
Acronym: PSILOCD
Sponsor: University of Arizona (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 15.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-01-02
Primary completion date: 2023-10-30
Completion date: 2023-12-30
Plan to share individual participant data: NO
Clinical trial NCT04501211: Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis
Official title: Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis and to Reduce Medical Utilization in Patients With Gastroparesis
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Abandoned due to limited resources
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-01
Primary completion date: 2020-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT04389450: Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19
Sponsor: Pluristem Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The decision to bring the Study to early clinical readout came in response to COVID-19's evolution as a disease, and the significant changes in the standard of care, leading to an increase in the severity of conditions of the intubated patients
Enrollment: 66.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-10-01
Primary completion date: 2021-05-17
Completion date: 2023-06-07
Plan to share individual participant data: NO
Clinical trial NCT04305184: A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)
Official title: A Phase 1/2, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of ASP0598 Otic Solution Following Topical Application Into the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Lack of Efficacy
Enrollment: 36.0 (ACTUAL)
Number of arms: 8.0
Start date: 2020-09-10
Primary completion date: 2023-01-24
Completion date: 2023-01-24
Baseline population: Safety Analysis Set (SAF) consisted of all randomized participants who received a dose of study drug.
Limitations and caveats: Due to limitations of the TM imaging data as evaluated by the central reader, secondary endpoints related to change in TMP size could not be fully evaluated. Following SAD and MAD data review by DMC, the single dose of ASP0598 Otic Solution provided insufficient efficacy to open the single dose expansion study.
Plan to share individual participant data: NO
IPD sharing description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under Sponsor Specific Details for Astellas.
Clinical trial NCT05122182: Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19
Official title: An Investigator Initiated, International Multi-Centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19
Acronym: CLARITY 2
Sponsor: University of Sydney (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Withdrawal of funding support from the trial funder.
Enrollment: 49.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-01-07
Primary completion date: 2022-08-15
Completion date: 2023-01-28
Plan to share individual participant data: YES
IPD sharing description: Trial data will be disseminated in the form of a publication to a relevant clinical journal and presentation at appropriate scientific conferences.~Individual participant data that underlie the results reported, after de-identification (text, tables, figures, and appendices), may be shared with Investigators whose proposed use of the data has been approved by an independent review committee (learned intermediary) identified for this purpose.
IPD access criteria: Data will be available after publication for an indefinite time / for a finite time (specify dates) All data requests will be considered by the primary sponsor on a case-by-case basis. Requests must include a methodologically sound proposal. Specific conditions of use may apply and will be specified in a data sharing agreement that the requester must agree to before access is granted.~Access can be requested via the Health Data Australia catalogue
Clinical trial NCT03517501: The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
Official title: Scarlet-2: A Randomized, Double-Blind,Placebo-Controlled, Phase 3 Study to Assess The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
Acronym: Scarlet2
Sponsor: Asahi Kasei Pharma America Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor will amend study design by incorporating reconfirmation of coagulopathy following discussion with FDA regarding findings from SCARLET1 study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-31
Primary completion date: 2022-04-30
Completion date: 2023-05-31
Plan to share individual participant data: NO
Clinical trial NCT04594031: US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease
Official title: A Phase I Multicenter Study of Hematopoietic Stem Cell Transplant of ECT-001-Expanded Cord Blood With a Reduced Toxicity Conditioning Regimen in Patients With Severe Sickle Cell Disease
Sponsor: ExCellThera inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Preference given to gene therapy approaches by the SCD research community and patients' associations
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-07-13
Primary completion date: 2023-09-01
Completion date: 2024-02-02
Plan to share individual participant data: NO
Clinical trial NCT02869243: A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
Official title: A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via Convection-Enhanced Delivery In Patients With Progressive And/Or Multiple Recurrent Glioblastoma Multiforme
Sponsor: Stemgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-18
Primary completion date: 2020-10-16
Completion date: 2021-06-30
Plan to share individual participant data: NO
Clinical trial NCT04708236: A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia
Official title: A Blinded, Controlled, Escalating Dose Study of ORTD-1 for Treatment of Hospitalized Patients With SARS-CoV-2 (COVID-19) Related Pneumonia.
Sponsor: Oryn Therapeutics, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: recruitment
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-04-30
Primary completion date: 2021-05-31
Completion date: 2021-07-31
Clinical trial NCT03015402: Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Official title: Phase II Clinical Investigation of Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
Acronym: PH-HFpEF
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-30
Primary completion date: 2023-01-25
Completion date: 2023-01-25
Limitations and caveats: This was a small clinical trial that under-enrolled due to the pandemic.
Clinical trial NCT05072080: A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
Official title: A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Sponsor: Bavarian Nordic (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 3258.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-09-29
Primary completion date: 2023-04-03
Completion date: 2023-04-03
Plan to share individual participant data: NO